MCID: PRS045
MIFTS: 50

Prostatic Hypertrophy

Categories: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

MalaCards integrated aliases for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 12 15 74
Benign Prostatic Hypertrophy 74
Prostatic Hyperplasia 74

Classifications:



External Ids:

Disease Ontology 12 DOID:11132

Summaries for Prostatic Hypertrophy

MalaCards based summary : Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to prostatic hyperplasia, benign and prostate cancer, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Alfuzosin and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and kidney, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 prostatic hyperplasia, benign 29.9 ADRA1A AR KLK3
2 prostate cancer 29.7 AR CYP19A1 EGF EGFR ESR1 KLK3
3 prostate cancer, hereditary, 8 10.4
4 prostate cancer, hereditary, 6 10.4
5 male reproductive organ benign neoplasm 10.3 CYP19A1 KLK3
6 vestibular gland benign neoplasm 10.3 ESR1 PGR
7 bartholin's gland adenoma 10.3 ESR1 PGR
8 vulvar syringoma 10.3 ESR1 PGR
9 lung leiomyoma 10.3 ESR1 PGR
10 glassy cell carcinoma of the cervix 10.3 ESR1 PGR
11 postmenopausal atrophic vaginitis 10.3 AR ESR1
12 nodular prostate 10.3 AR KLK3
13 vaginitis 10.3 AR ESR1
14 vulvar benign neoplasm 10.3 ESR1 PGR
15 trigonitis 10.3 ESR1 PGR
16 vulvar leiomyoma 10.3 ESR1 PGR
17 predominantly cortical thymoma 10.3 ESR1 PGR
18 androgen insensitivity, partial 10.3 AR CYP19A1
19 breast medullary carcinoma 10.3 ESR1 PGR
20 bartholin's gland benign neoplasm 10.3 ESR1 PGR
21 progesterone resistance 10.3 ESR1 PGR
22 cribriform carcinoma 10.3 ESR1 PGR
23 transsexualism 10.3 AR CYP19A1
24 endometrial mucinous adenocarcinoma 10.3 ESR1 PGR
25 adenoid basal cell carcinoma 10.3 ESR1 PGR
26 benign metastasizing leiomyoma 10.3 CYP19A1 PGR
27 sebaceous adenoma 10.3 EGF ESR1
28 deep angioma 10.3 ESR1 PGR
29 alopecia, androgenetic, 1 10.3 AR CYP19A1
30 synchronous bilateral breast carcinoma 10.3 ESR1 PGR
31 muscle hypertrophy 10.3
32 female reproductive endometrioid cancer 10.3 ESR1 PGR
33 cervical carcinosarcoma 10.3 ESR1 PGR
34 intramuscular hemangioma 10.2 ESR1 PGR
35 glycogen-rich clear cell breast carcinoma 10.2 ESR1 PGR
36 cervical clear cell adenocarcinoma 10.2 ESR1 PGR
37 retinitis pigmentosa 47 10.2 ESR1 PGR
38 endometrial disease 10.2 CYP19A1 ESR1
39 corneal abscess 10.2 AR PGR
40 bartholin's gland disease 10.2 AR PGR
41 calcifying aponeurotic fibroma 10.2 EGF PGR
42 retinitis pigmentosa 20 10.2 ESR1 PGR
43 adenosarcoma 10.2 ESR1 PGR
44 endometrial stromal nodule 10.2 CYP19A1 PGR
45 breast benign neoplasm 10.2 ESR1 PGR
46 papillary hidradenoma 10.2 AR PGR
47 thoracic benign neoplasm 10.2 ESR1 PGR
48 androgenic alopecia 10.2 AR CYP19A1 KLK3
49 aromatase deficiency 10.2 CYP19A1 ESR1
50 progesterone-receptor negative breast cancer 10.2 EGFR PGR

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Cancer
Bladder Disease Bladder Neck Obstruction
Chronic Kidney Failure Chronic Myocardial Ischemia
Cystitis Cystitis Cystica
Epididymo-Orchitis First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Hydronephrosis Infected Hydrocele
Interstitial Cystitis Ischemic Heart Disease
Kidney Disease Left Bundle Branch Hemiblock
Lipoma of Spermatic Cord Low Compliance Bladder
Nephrolithiasis, X-Linked Recessive, with Renal Failure Neurogenic Bladder
Parkinson Disease, Late-Onset Pelvic Varices
Penile Disease Peyronie's Disease
Pinta Disease Pneumoconiosis
Postinflammatory Pulmonary Fibrosis Prostate Calculus
Prostate Cancer Prostate Carcinoma in Situ
Prostate Disease Prostatitis
Prostatocystitis Renal Pelvis Carcinoma
Right Bundle Branch Block Silicosis
Spermatocele Ureter, Cancer of
Ureterolithiasis Urethral Benign Neoplasm
Urethral Calculus Urethral Stricture
Urethritis Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 ADRA1A AR CD36 CYP19A1 ESR1 FGF8
2 cardiovascular system MP:0005385 10.1 ADRA1A AR CD36 CYP19A1 EGFR ESR1
3 immune system MP:0005387 10.09 AR CD36 CYP19A1 EGF EGFR ESR1
4 endocrine/exocrine gland MP:0005379 10.06 AR CD36 CYP19A1 EGF EGFR ESR1
5 digestive/alimentary MP:0005381 10.02 AR CD36 CYP19A1 EGF EGFR ESR1
6 adipose tissue MP:0005375 9.92 AR CD36 CYP19A1 EGFR ESR1
7 muscle MP:0005369 9.92 ADRA1A AR CD36 CYP19A1 EGFR ESR1
8 integument MP:0010771 9.88 AR CYP19A1 EGF EGFR ESR1 PGR
9 normal MP:0002873 9.8 AR CYP19A1 EGF EGFR ESR1 FGF8
10 limbs/digits/tail MP:0005371 9.77 AR EGFR ESR1 FGF8 PGR
11 renal/urinary system MP:0005367 9.7 ADRA1A AR CD36 CYP19A1 EGFR ESR1
12 reproductive system MP:0005389 9.5 AR CYP19A1 EGF EGFR ESR1 FGF8
13 skeleton MP:0005390 9.17 AR CD36 CYP19A1 EGFR ESR1 FGF8

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alfuzosin Approved, Investigational Phase 4,Phase 3,Not Applicable 81403-80-7 2092
2
Tamsulosin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 106133-20-4 129211
3
Mirabegron Approved Phase 4 223673-61-8 9865528
4
Silodosin Approved Phase 4 160970-54-7
5
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
6
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
7
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
8
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 58-22-0, 481-30-1 6013 10204
9
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
10
Dihydrotachysterol Approved Phase 4 67-96-9 5281010 5311071
11
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
12
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
13
Dutasteride Approved, Investigational Phase 4,Phase 3,Not Applicable 164656-23-9 152945 6918296
14
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
15 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
16 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
19 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Mitogens Phase 4,Not Applicable
21 Adrenergic beta-3 Receptor Agonists Phase 4
22 Adrenergic Agonists Phase 4,Not Applicable
23 Adrenergic beta-Agonists Phase 4
24 Neuromuscular Blocking Agents Phase 4
25 Neuromuscular Nondepolarizing Agents Phase 4
26 Anesthetics Phase 4,Not Applicable
27 Cholinergic Agents Phase 4,Phase 3,Phase 2
28 Cholinergic Antagonists Phase 4,Phase 2,Phase 3
29 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
30 Neuromuscular Agents Phase 4,Phase 3
31 Solifenacin succinate Phase 4 242478-38-2
32 Muscarinic Antagonists Phase 4,Phase 2,Phase 3
33 Antineoplastic Agents, Hormonal Phase 4,Phase 2
34 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 Anabolic Agents Phase 4,Phase 2
36 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
38 Testosterone 17 beta-cypionate Phase 4,Phase 2
39 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
40 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Androgens Phase 4,Phase 3,Phase 2,Not Applicable
42 Parasympatholytics Phase 4
43
Cetrorelix Approved, Investigational Phase 3 120287-85-6 25074887 16129715
44
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
45
Finasteride Approved Phase 3,Phase 1,Phase 2,Not Applicable 98319-26-7 57363
46
Doxazosin Approved Phase 3 74191-85-8 3157
47
Prazosin Approved Phase 3,Not Applicable 19216-56-9 4893
48
Norepinephrine Approved Phase 3 51-41-2 439260
49 Antihypertensive Agents Phase 3,Not Applicable
50 Fertility Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy Completed NCT00542165 Phase 4 Alfuzosin
2 A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
3 Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH Completed NCT01260129 Phase 4 Silodosin;Silodosin
4 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4 Surgical block (rocuronium; atracurium/mivacurium);Surgical block (rocuronium; atracurium/mivacurium)
5 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
6 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
7 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
8 Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms Completed NCT01457573 Phase 4 Tamsulosin;Solifenacin
9 Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Enrolling by invitation NCT02958878 Phase 4 Tamsulosin;Placebo Oral Capsule
10 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Completed NCT00663858 Phase 3 Cetrorelix 78+78;Cetrorelix 78 + Placebo
11 The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate Completed NCT00427219 Phase 2, Phase 3 Ozarelix/Placebo;Placebo
12 A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy Completed NCT01275521 Phase 3 BONT-A intra-prostatic injection;Optimized medical BPH treatment
13 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT00670306 Phase 3 Cetrorelix Pamoate
14 Study to Assess the Efficacy of Medi-Tate iTind Device Completed NCT02145208 Phase 3
15 Medical Therapy of Prostatic Symptoms Completed NCT00021814 Phase 3 Doxazosin;Finasteride;Doxazosin placebo;Finasteride placebo
16 Clinical Trial in Males With BPH (Enlarged Prostate) Completed NCT00029822 Phase 3 Alfuzosin (SL770499)
17 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3 Dutasteride;Placebo
18 Combined Behavioral and Drug Treatment of Overactive Bladder in Men Completed NCT01175382 Phase 2, Phase 3 Tolterodine + tamsulosin
19 Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests Recruiting NCT03539614 Phase 3 Prazosin;Placebo
20 Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Terminated NCT00449150 Phase 3 Cetrorelix 78 mg + 78 mg;Cetrorelix 78 mg + 52 mg;Placebo
21 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3 Finasteride
22 A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH). Unknown status NCT00044226 Phase 2 ML-04A
23 Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy Completed NCT00461123 Phase 2 Vardenafil (Levitra, BAY38-9456);Placebo
24 Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00386009 Phase 2 Tadalafil;Placebo
25 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
26 A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Completed NCT00154843 Phase 2 Lycopene
27 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
28 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2 Testosterone Enanthate;Finasteride
29 Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH) Recruiting NCT02676544 Phase 1, Phase 2
30 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
31 Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter Active, not recruiting NCT03423979 Phase 2 Paclitaxel
32 Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy Active, not recruiting NCT01446991 Phase 2 Degarelix;Degarelix
33 Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams Terminated NCT02396420 Phase 2
34 Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH) Completed NCT01330927 Phase 1 VA106483
35 A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects Completed NCT02615782 Phase 1 CKD-397
36 Prazosin Use in Adults With Anxiety Disorders Recruiting NCT03894345 Phase 1 Prazosin
37 Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia Recruiting NCT02592473 Phase 1
38 Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) Unknown status NCT00256399 Not Applicable Alfuzosin 10 mg
39 Comparison of Different Energy Sources During TUR-P Unknown status NCT02533687 Not Applicable
40 Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia Unknown status NCT01781117 Not Applicable
41 The Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients Unknown status NCT01070602 Not Applicable
42 The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer Unknown status NCT01089881
43 Rezum FIM Optimization Unknown status NCT02940392 Not Applicable
44 Rezum I Pilot Study for BPH Unknown status NCT02943070 Not Applicable
45 Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS) Unknown status NCT02024100
46 Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan Completed NCT01323998 5ARI;AB
47 MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer Completed NCT00706966 Not Applicable dutasteride
48 Plasmakinetic Enucleation of the Prostate to Treat Benign Prostatic Hypertrophy Patients With Large Prostate Completed NCT01637701 Not Applicable
49 Safety and Efficacy of OCL 503 in Prostate Artery Embolization Completed NCT02509975 Not Applicable
50 Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound Completed NCT01732991 Not Applicable

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

MalaCards organs/tissues related to Prostatic Hypertrophy:

42
Prostate, Testes, Kidney, Liver, Heart, Breast, Bone

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 569)
# Title Authors Year
1
Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. ( 29679999 )
2018
2
Investigational procedures in benign prostatic hypertrophy. ( 29528973 )
2018
3
Benign prostatic hypertrophy: PycnogenolAr supplementation improves prostate symptoms and residual bladder volume. ( 29947491 )
2018
4
Silodosin for benign prostatic hypertrophy. ( 30116085 )
2018
5
Drugs for benign prostatic hypertrophy. ( 30410211 )
2018
6
Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy. ( 27853823 )
2017
7
Investigating the link between benign prostatic hypertrophy, BMI and type 2 diabetes mellitus. ( 28433616 )
2017
8
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway. ( 28332240 )
2017
9
Case-Control Study of Intra-arterial Verapamil for Intraprostatic Anastomoses to Extraprostatic Arteries in Prostatic Artery Embolization for Benign Prostatic Hypertrophy. ( 28506701 )
2017
10
Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. ( 28593165 )
2017
11
Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study. ( 29048765 )
2017
12
The androgen receptor plays different roles in macrophage-induced proliferation in prostate stromal cells between transitional and peripheral zones of benign prostatic hypertrophy. ( 28694768 )
2017
13
Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. ( 28609136 )
2017
14
Donegal Going against the Flow: National Differences in Long-Term Urinary Catheterisation Rates in Men (> 65 Years) With Benign Prostatic Hypertrophy. ( 29372955 )
2017
15
Re: Stroke Associated with Alpha Blocker Therapy for Benign Prostatic Hypertrophy. ( 27321530 )
2016
16
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with I+-blockers. ( 27629686 )
2016
17
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5I+-Reductase Associated with Benign Prostatic Hypertrophy. ( 27399661 )
2016
18
Kidney transplant complications from undiagnosed benign prostatic hypertrophy. ( 25832848 )
2015
19
Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. ( 26290288 )
2015
20
The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. ( 26543428 )
2015
21
Supplementary management of benign prostatic hypertrophy with Prostaquil. An 8-week registry. ( 26492588 )
2015
22
Clinical Outcomes of Transurethral Enucleation with Bipolar for Benign Prostatic Hypertrophy. ( 26662662 )
2015
23
The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. ( 26438220 )
2015
24
Effects of I+-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. ( 25735029 )
2015
25
Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. ( 25587300 )
2014
26
Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. ( 24754254 )
2014
27
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. ( 25348255 )
2014
28
Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study. ( 25606561 )
2014
29
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. ( 24892642 )
2014
30
Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. ( 24744521 )
2014
31
Tadalafil and benign prostatic hypertrophy. Too risky. ( 24860894 )
2014
32
Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report and review of the literature. ( 24513237 )
2014
33
Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 25629105 )
2014
34
Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 24120797 )
2013
35
A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 23642948 )
2013
36
Successful minimally-invasive management of a case of giant prostatic hypertrophy associated with recurrent nephrogenic adenoma of the prostate. ( 23565707 )
2013
37
Alpha-1 adrenergic antagonists in aircrew for the treatment of benign prostatic hypertrophy. ( 23305000 )
2013
38
Correlation of transrectal and transabodominal ultrasound measurement of transition zone volume with post-operative enucleated adenoma volume in benign prostatic hypertrophy. ( 24876907 )
2013
39
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. ( 22123290 )
2012
40
On call. As a retired physician, I particularly appreciate "Harvard Men's Health Watch" since it's an easy way for me to learn about new developments in medicine. As a 78-year-old man with an enlarged prostate, I'm particularly interested in your fine articles about BPH. But if memory serves me right, we called the condition "benign prostatic hypertrophy" when I was in practice, but now you call it "benign prostatic hyperplasia." What's the difference? ( 22670285 )
2012
41
Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 23089217 )
2012
42
The early days of prostatectomy for benign prostatic hypertrophy. ( 22132481 )
2011
43
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( 21962427 )
2011
44
Sphaeranthus indicus attenuates testosterone induced prostatic hypertrophy in albino rats. ( 21503998 )
2011
45
[Sexual problems in patients with prostate cancer and those with benign prostatic hypertrophy]. ( 21542379 )
2011
46
Analysis of the Pressure-Flow Study in Weak Detrusor Patients with Benign Prostatic Hypertrophy. ( 26676396 )
2011
47
Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy. ( 21221201 )
2010
48
Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. ( 20944533 )
2010
49
Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. ( 24688153 )
2010
50
Increased frequency and nocturia in a middle aged male may not always be due to Benign Prostatic Hypertrophy (BPH): a case report. ( 19946479 )
2009

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

Pathways related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 AR EGF EGFR KLK3
2
Show member pathways
12.43 EGF EGFR ESR1 FGF8
3
Show member pathways
12.43 EGF EGFR ESR1 FGF8 PGR
4 11.82 AR EGF EGFR ESR1 FGF8 KLK3
5 11.75 AR CYP19A1 EGFR ESR1
6 11.63 AR EGFR KLK3
7
Show member pathways
11.62 AR EGF EGFR KLK3
8
Show member pathways
11.61 AR ESR1 PGR
9 11.45 EGF EGFR ESR1
10
Show member pathways
11.29 EGF EGFR ESR1 PGR
11 11.26 CD36 EGFR ESR1
12
Show member pathways
11.16 AR ESR1 KLK3
13 11.1 CYP19A1 PGR
14 11.08 EGF EGFR
15 11 EGF EGFR
16
Show member pathways
10.97 EGF EGFR
17 10.95 EGF EGFR
18 10.85 EGF EGFR FGF8
19 10.66 EGF EGFR
20 10.03 CYP19A1 ESR1

GO Terms for Prostatic Hypertrophy

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.94 AR EGF EGFR FGF8
2 positive regulation of gene expression GO:0010628 9.87 AR CD36 EGF FGF8
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 ADRA1A CD36 EGFR FGF8
4 peptidyl-tyrosine phosphorylation GO:0018108 9.77 EGF EGFR FGF8
5 transcription initiation from RNA polymerase II promoter GO:0006367 9.77 AR ESR1 PGR
6 positive regulation of cytosolic calcium ion concentration GO:0007204 9.75 ADRA1A CD36 ESR1
7 positive regulation of vasoconstriction GO:0045907 9.64 ADRA1A EGFR
8 activation of phospholipase C activity GO:0007202 9.63 ADRA1A EGFR
9 ERBB2 signaling pathway GO:0038128 9.62 EGF EGFR
10 regulation of cell motility GO:2000145 9.62 EGF EGFR
11 positive regulation of protein kinase B signaling GO:0051897 9.62 EGF EGFR ESR1 FGF8
12 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.61 EGF EGFR
13 positive regulation of mitotic nuclear division GO:0045840 9.61 EGF FGF8
14 steroid hormone mediated signaling pathway GO:0043401 9.61 AR ESR1 PGR
15 response to lipid GO:0033993 9.58 CD36 EGFR
16 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.56 EGF EGFR
17 uterus development GO:0060065 9.55 CYP19A1 ESR1
18 androgen metabolic process GO:0008209 9.54 CYP19A1 ESR1
19 regulation of systemic arterial blood pressure GO:0003073 9.52 AR KLK3
20 prostate gland growth GO:0060736 9.51 AR CYP19A1
21 negative regulation of ERBB signaling pathway GO:1901185 9.48 EGF EGFR
22 regulation of toll-like receptor signaling pathway GO:0034121 9.46 CD36 ESR1
23 positive regulation of MAPK cascade GO:0043410 9.43 ADRA1A AR CD36
24 morphogenesis of an epithelial fold GO:0060571 9.4 AR EGFR
25 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.37 AR PGR
26 positive regulation of phosphorylation GO:0042327 9.33 AR EGF EGFR
27 phosphatidylinositol phosphorylation GO:0046854 9.26 EGF EGFR ESR1 FGF8
28 mammary gland alveolus development GO:0060749 8.8 AR EGF ESR1
29 signal transduction GO:0007165 10.11 ADRA1A AR EGF EGFR ESR1 PGR

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.73 AR EGFR ESR1 PGR
2 lipid binding GO:0008289 9.67 AR CD36 ESR1 PGR
3 protein tyrosine kinase activity GO:0004713 9.65 EGF EGFR FGF8
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.63 EGF EGFR FGF8
5 ATPase binding GO:0051117 9.5 AR ESR1 PGR
6 steroid hormone receptor activity GO:0003707 9.43 AR ESR1 PGR
7 nitric-oxide synthase regulator activity GO:0030235 9.4 EGFR ESR1
8 nuclear receptor activity GO:0004879 9.33 AR ESR1 PGR
9 steroid binding GO:0005496 9.13 AR ESR1 PGR
10 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 EGF EGFR ESR1 FGF8

Sources for Prostatic Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....